Treatment of alcoholic liver disease.
Alcoholic liver disease (ALD) remains a major cause of morbidity and mortality worldwide. For example, the Veterans Administration Cooperative Studies reported that patients with cirrhosis and superimposed alcoholic hepatitis had a 4-year mortality of >60% (worse than many common cancers such as breast and prostate). The cornerstone for therapy for ALD is lifestyle modification, including drinking cessation and treatment of decompensation, if appropriate. Nutrition intervention has been shown to play a positive role on both an in-patient and out-patient basis. Corticosteroids are effective in selected patients with alcoholic hepatitis, and treatment with pentoxifylline appears to be a promising anti-inflammatory therapy. Recent studies have indicated anti-TNFalpha therapy, at least for alcoholic hepatitis. Some complementary and alternative medicinal agents, such as milk thistle and S-adenosylmethionine, may be effective in alcoholic cirrhosis. Treatment of the complications of ALD can improve the quality of life and, in some cases, decrease short-term mortality.
Bergheim
Ina
I
Department of Pharmacology and Toxicology, University of Louisville Health Sciences Center, Louisville, KY 40292, USA.
McClain
Craig J
CJ
Arteel
Gavin E
GE
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D000529:Complementary Therapies / Q000379:methods; D004032:Diet; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008108:Liver Diseases, Alcoholic / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D008111:Liver Function Tests; D008297:Male; D010431:Pentoxifylline / Q000627:therapeutic use*; D011379:Prognosis; D018570:Risk Assessment; D012720:Severity of Illness Index; D016019:Survival Analysis; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D004791:Enzyme Inhibitors; D010431:Pentoxifylline